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Abstract
 
Effective immune surveillance is essential for maintaining protection and homeostasis of peripheral
tissues. However, mechanisms controlling memory T cell migration to peripheral tissues such
as the skin are poorly understood. Here, we show that the majority of human T cells in healthy
skin express the chemokine receptor CCR8 and respond to its selective ligand I-309/CCL1.
These CCR8
 
 
 
 T cells are absent in small intestine and colon tissue, and are extremely rare in
peripheral blood, suggesting healthy skin as their physiological target site. Cutaneous CCR8
 
 
 
T cells are preactivated and secrete proinflammatory cytokines such as tumor necrosis factor–
 
 
 
and interferon-
 
 
 
, but lack markers of cytolytic T cells. Secretion of interleukin (IL)-4, IL-10,
and transforming growth factor–
 
 
 
 was low to undetectable, arguing against a strict association
of CCR8 expression with either T helper cell 2 or regulatory T cell subsets. Potential precursors
of skin surveillance T cells in peripheral blood may correspond to the minor subset of
CCR8
 
 
 
CD25
 
 
 
 T cells. Importantly, CCL1 is constitutively expressed at strategic cutaneous
locations, including dermal microvessels and epidermal antigen-presenting cells. For the first
time, these findings define a chemokine system for homeostatic T cell traffic in normal human skin.
Key words: chemokine • CCR8 • peripheral tissue • memory T cells • migration
 
Introduction
 
Numerous chemokines contribute to the composition of
inflammatory cell infiltrates (1–4). These “inflammatory”
chemokines are produced locally at the site of pathogen entry
or tissue damage in response to multiple proinflammatory
and microbial stimuli and mediate extravasation and recruit-
ment of effector leukocytes. Pathogen elimination ultimately
results in the establishment of an immune memory for en-
hanced protection against repeated exposure to the same
pathogen. Currently, two types of memory T cells in periph-
eral blood have been described that are characterized by
mutually exclusive tissue-homing properties (5). Central
memory T cells (T
 
CM
 
) express L-selectin (CD62L) and the
chemokine receptor CCR7 for efficient traffic through
secondary lymphoid tissues. In contrast, effector memory T
cells (T
 
EM
 
) lack these migration receptors and, therefore,
are excluded from LNs and splenic T cell areas, but can enter
sites of inflammation in the periphery. In mice, long-lived
T
 
CM
 
 may develop from T
 
EM
 
 (6). Of note, the T
 
CM
 
–T
 
EM
 
distinction is not strict because CCR7
 
 
 
 T cells are also
found at inflammatory sites, and CCR7
 
 
 
 effector T cells
may enter reactive LNs (4).
In contrast with LNs and sites of inflammation, the
mechanisms controlling the homing of memory T cells to
peripheral tissues under steady-state (noninflamed) conditions
are poorly defined. Such “immune surveillance” T cells are
likely to have tissue-selective address codes that differ from
those of either T
 
CM
 
 (secondary lymphoid tissues) or T
 
EM
 
(inflammation). Tissue selectivity is conferred in part by ad-
hesion molecules, such as 
 
 
 
4
 
 
 
7
 
 on gastrointestinal T cells
and cutaneous lymphocyte-associated antigen (CLA) on
cutaneous T cells, whose respective ligands (the mucosal
vascular addressin MAdCAM-1 and E-selectin) are present
on the microvasculature within gut and skin tissue (7). In
addition, immune surveillance T cells need to respond to
homeostatic chemokines that are constitutively expressed
in healthy peripheral tissues, thereby clearly differing from
effector cells that are recruited to inflamed sites in response
 
The online version of this article contains supplemental material.
Address correspondence to Bernhard Moser, Theodor-Kocher Institute,
University of Bern, P.O. Box 99, CH-3000 Bern 9, Switzerland. Phone: 41-
31-631-4157; Fax: 41-31-631-3799; email: bernhard.moser@tki.unibe.ch
 
Abbreviations used in this paper:
 
 CLA, cutaneous lymphocyte-associated
antigen; LC, Langerhans cell; T
 
CM
 
, central memory T cells; T
 
EM
 
, effector
memory T cells; Treg, T regulatory. 
Normal Human Skin Harbors CCR8-expressing Memory T Cells
 
1266
to inducible chemokines (2–4). The chemokine receptor
CCR9 is prominently expressed by small intestinal T cells,
and its single ligand TECK/CCL25 is produced by crypt
epithelial cells and proximal endothelial cells in the small
intestine, which suggests that this chemokine may contrib-
ute to local T cell traffic (3, 8–10). It is unclear at present
which chemokine systems contribute the steady-state traffic
of immune surveillance T cells at other sites of the gas-
trointestinal tract.
The skin forms the primary barrier between the body and
the environment and is subject to continuous insults that in-
clude microbes, chemicals, UV irradiation, and tissue dis-
ruption. Integrity of the skin critically depends on an ade-
quate skin-selective immune system because malfunction
can lead to a multitude of local diseases (e.g., tumors, psori-
asis, and atopic dermatitis; references 11–13). The cutaneous
immune system consists of sentinel cells, including macro-
phages, DCs, and mast cells as well as memory T cells that
reflect previous vaccination responses. Understanding the
mechanisms by which these cells are recruited and posi-
tioned within the skin is crucial to understand, and eventu-
ally manipulate, the cutaneous immune system for thera-
peutic benefits. Here, we report that I-309/CCL1 and its
single receptor CCR8 fulfill the requirements for control-
ling the steady-state traffic of cutaneous memory T cells.
CCL1 was one of the first chemokines discovered, and
after 16 yr of investigation, numerous target cells and cellu-
lar responses have been reported, including those related to
tumor cell apoptosis, angiogenesis, and HIV-1 infection as
well as blood and tissue cell chemotaxis. However, the
cloning of CCR8 mRNA revealed the scarcity of this che-
mokine receptor, notably in peripheral blood leukocytes
(14–17). Recently, CCR8 positivity was found in thy-
mocytes (18–21), cultured Th2 (22–25), and CD4
 
 
 
CD25
 
 
 
T regulatory (Treg) cells (20, 26, 27). The role of CCR8 in
the physiology of these cell types is still unclear. Here, using
a novel anti-CCR8 antibody reagent, we demonstrate that
healthy skin is a major reservoir of CCR8
 
 
 
 T cells, which
consist of cytokine-producing but not cytotoxic CD4
 
 
 
and CD8
 
 
 
 T cells. In peripheral blood, potential precursors
of skin immune surveillance T cells were identified as
CCR8
 
 
 
CD25
 
 
 
 T cells rather than Treg cells, which ex-
press low levels of CCR8. Importantly, CCL1 is constitu-
tively expressed within the dermal microvasculature, as well
as by epidermal Langerhans cells (LCs) and melanocytes.
Together, these findings support a unique role for this che-
mokine system in the tissue localization of memory T cells
during cutaneous immune surveillance.
 
Materials and Methods
 
Antibodies and ELISA. 
 
Fluorochrome-conjugated antibod-
ies to human proteins were purchased from the following
sources: rat antibodies to CLA (HECA-452), IL-5 (JES1-39D10),
IL-10 (JES3-9D7), and IL-13 (JES10-5A2); and mouse antibodies
to CD3 (UCHT1), CD4 (RPA-T4), CD8 (HIT8a), CD11b
(D12), CD25 (M-A251), CD27 (M-T271), CD45RA (HI100),
CD45RO (UCHL1), CD57 (Leu-7), CD69 (FN50), HLA-DR
(G46–6), TCR-
 
 
 
/
 
 
 
-1 (WT31), perforin (dG9), CCR4 (1G1),
CCR5 (2D7), CCR6 (11A9), CXCR3 (1C6), IL-2 (5344.111),
IL-4 (3010.211), IL-6 (AS12), IL-8 (AS14), TNF-
 
 
 
 (6401.1111),
and IFN-
 
 
 
 (25723.11) were obtained from BD Biosciences. Rat
antibody to CCR7 (3D12; M. Lipp, Max-Delbruck-Center for
Molecular Medicine, Berlin, Germany) was detected by a bio-
tinylated donkey anti–rat IgG obtained from Jackson Immuno-
Research Laboratories, followed by PE-conjugated streptavidin
(DakoCytomation). OptEIA ELISA kits for the detection of IL-4,
IL-10, IFN-
 
 
 
, TNF-
 
 
 
, and TGF-
 
 
 
 in supernatants were ob-
tained from BD Biosciences. The CCL1 ELISA assay was devel-
oped using monoclonal anti-CCL1 (clone 35305.11) as capture
antibody and a biotinylated goat anti-CCL1 polyclonal antibody
for detection (both obtained from R&D Systems) in combination
with synthetic CCL1 for the generation of a standard curve.
 
Medium and Cell Preparations. 
 
Complete medium consisted of
RPMI 1640, 2 mM 
 
l
 
-glutamine, 1% nonessential amino acids, 1%
sodium pyruvate, 50 
 
 
 
g/ml penicillin/streptomycin, 5 
 
 
 
 10
 
 
 
5
 
 M
2-mercaptoethanol (Invitrogen), and 10% heat-inactivated FCS
(Biological Ind.). Human PBMCs were isolated from fresh blood
by centrifugation on Ficoll-Paque. Pure (
 
 
 
99%) 
 
  
 
TCR
 
 
 
 cells
were obtained by positive selection using anti-
 
  
 
TCR (BMA031)
antibodies (Caltag Lab.) and goat anti–mouse MicroBead IgG
(Miltenyi Biotec). Pure (
 
 
 
98%) CD4
 
 
 
CD25
 
 
 
 T cells from PBMCs
were obtained by depletion of non-CD4
 
 
 
 T cells followed by
positive selection of CD25
 
 
 
 cells (Miltenyi Biotec). Cell lines
were generated by sorting CCR8
 
 
 
 and CCR8
 
 
 
 cells from CD4
 
 
 
(or CD8
 
 
 
) CD25
 
 
 
CD45RA
 
 
 
CD45RO
 
 
 
 T cells. 5,000 sorted
cells were stimulated with 500,000 allogeneic PBMCs (irradiated
40 Gy) and twice 50,000 EBV-transformed B cells (from two do-
nors, 70 Gy) in complete medium containing 1,000 U/ml IL-2.
Skin T cells were isolated as follows: normal abdominal skin was
excised using a dermatome (0.3–0.5 mm thick), and 100 cm
 
2
 
 sec-
tions were digested in 10 ml RPMI 1640 containing 1 mg/ml col-
lagenase D (Roche) for 30 min at 37
 
 
 
C on a shaker. Digestion was
stopped by adding 10 mM EDTA and immediate cooling and pro-
cessing on ice. Floating cells were collected and pooled with cells
obtained by washing the remaining tissue several times with ice-
cold PBS
 
 
 
/10 mM EDTA (minimum 10
 
 
 
 excess of digestion
volume). Cells were passed through a 70-
 
 
 
m pore nylon mesh
(BD Biosciences) and centrifuged (300 
 
g
 
) for 20 min at 4
 
 
 
C. After
resuspension in cold complete medium, cells were passed through
a 40-
 
 
 
m pore mesh and centrifuged on a Ficoll-Paque gradient
(600 
 
g
 
; 20 min at 4
 
 
 
C). Interphase cells consisted of 
 
 
 
90% viable T
cells (as judged by CD45, 
 
  
 
TCR, and propidium iodide stain-
ing). Bulk T cells were sorted into 
 
  
 
TCR
 
 
 
CCR8
 
 
 
CD8
 
 
 
 or
 
  
 
TCR
 
 
 
CCR8
 
 
 
CD8
 
 
 
 cells for single cell cloning or intracellular
cytokine analysis. Skin T cells were allowed to recover for 3 h in
complete medium at 37
 
 
 
C before chemotaxis assay was performed.
Skin T cell clones were generated by single cell sorting and cul-
tured under nonpolarizing conditions (10 ng/ml of recombinant
TGF-
 
 
 
 [R&D Systems], 1 
 
 
 
g/ml anti–IL-4 [MP4–25D2], and 2
 
 
 
g/ml anti–IL-12 [C8.6; BD Biosciences]) as described previously
(28). Clones were expanded in culture for 2 wk or longer before
analysis. Gastrointestinal lamina propria and intraepithelial T cells
were isolated from healthy small intestinal and colon tissue accord-
ing to standard procedure (9).
 
Proliferation Assay. 
 
To assess inhibitory activities of CD4
 
 
 
CD25
 
 
 
 T cell subsets, 50,000 allogeneic, irradiated (40 Gy) PBMCs
(depleted from CD3
 
 
 
 T cells) were mixed with 50,000 CD4
 
 
 
CD25
 
 
 
CD45RA
 
 
 
 (responder) T cells and 50,000 CD4
 
 
 
CD25
 
 
 
 T
cells of the following phenotypes (obtained by cell sorting): CD25
 
 
 
CLA
 
 
 
CCR8
 
 
 
, CD25
 
 
 
CLA
 
 
 
CCR8
 
 
 
, and CD25
 
 
 
CLA
 
 
 
CCR8
 
 
 
. 
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[
 
3
 
H]Thymidine incorporation was measured in triplicates on day 5
after a 10-h pulse (0.5 
 
 
 
Ci/round-bottom 96-well plates). Com-
plete medium did not contain exogenous IL-2.
 
Intracellular Cytokine/Perforin Analysis. 
 
Sorted 
 
  
 
TCR
 
 
 
CCR8
 
 
 
CD8
 
 
 
 or 
 
  
 
TCR
 
 
 
CCR8
 
 
 
CD8
 
 
 
 skin T cells, or skin T
cell clones, were stimulated with 10 ng/ml PMA, 1 
 
 
 
g/ml iono-
mycin, and 10 
 
 
 
g/ml brefeldin A (Qbiogene) for 4.5–10 h. After
fixing with 2% paraformaldehyde for 20 min at 4
 
 
 
C and per-
meabilization with 0.2% saponin/2% FCS in PBS
 
 
 
, cells were
stained with antibodies and analyzed by flow cytometry. Perforin
was examined without prior cell activation.
 
Chemotaxis. 
 
Transwell chemotaxis assays were performed us-
ing a 5-
 
 m pore polycarbonate filter (Corning Costar Corp.)
loaded with 400,000 skin T cells. Migrated cells were collected
from the lower well and stained and quantified by flow cytometry
using a fixed number of polystyrene beads. The modified Boy-
den chamber assay (Neuroprobe) was conducted using collagen-
coated 5- m pore polycarbonate filters. Wells were loaded with
105 cells, and those that had migrated to the filter underside after 1 h
at 37 C were stained and counted in five high-power fields.
Immunohistochemistry.  Skin samples from healthy donors un-
dergoing abdominal reduction were formaldehyde fixed and par-
affin embedded. Freshly prepared 5- m tissue sections were de-
waxed and rehydrated. After pretreatment with 1 mg/ml protease
from Streptomyces griseus (Sigma-Aldrich) in Tris-buffered saline for
6 min at 37 C or heat-induced epitope retrieval, sections were
blocked with 3 mg/ml Redimune (ZLB Bioplasma AG), 10%
donkey or rabbit serum (Jackson ImmunoResearch Laboratories
and DakoCytomation), 0.01% Tween 20 and 0.01% sodium azide
in Tris-buffered saline. Sections were incubated overnight at 4 C
with primary antibodies to CCL1 (Santa Cruz Biotechnology,
Inc.); podoplanin (AngioBio); CD31 (JC70A); S100, Vimentin
(Vim3B4), CD1a (010), CD3, melan-A (A103), and isotype con-
trol antibodies mouse IgG2a (all obtained from DakoCytoma-
tion); rabbit IgG (Jackson ImmunoResearch Laboratories); and
mouse IgG1 (MOPC21) and goat IgG (both obtained from
Sigma-Aldrich). Subsequent detection of single bound antibodies
was performed by the avidin–biotin enzyme complex method.
Alternatively, multicolor staining was obtained by immunofluo-
rescence using Alexa Fluor 488–conjugated chicken anti–mouse
Ig (Molecular Probes) in combination with biotinylated donkey
anti–sheep/goat Ig (The Binding Site) and Alexa Fluor 594–con-
jugated streptavidin (Molecular Probes). Primary rabbit antibodies
were additionally bridged with mouse anti–rabbit antibodies (Da-
koCytomation). Cell nuclei were counterstained in blue by 4 ,6 -
diamino-2-phenylindole present in the mounting medium Slow-
Fade Light (Molecular Probes). Two-dimensional images were
recorded by wide-field microscopy. For statistical analysis of
CCL1 coexpression with CD31 or S100, CD31 positive vessels of
the superficial dermal plexus and S-100 positive cells (LCs and
melanocytes) were analyzed in sections from eight different skin
tissues samples obtained from three separate donors.
Online Supplemental Material.  Anti–human CCR8 antibod-
ies were generated by immunizing rabbits with a human CCR8
peptide conjugate, corresponding to positions 1–34 of the NH2-
terminal region of CCR8 coupled to either KLH or BSA in Spe-
col (Institute for Animal Science and Health, The Netherlands),
and purified by CCR8 peptide–agarose chromatography. Specific-
ity was determined by flow cytometry using stably transfected 300-
19 pre–B cells expressing CCR8 or other human chemokine re-
ceptors. Affinity-purified rabbit anti-CCR8 was detected by a
biotinylated donkey anti–rabbit IgG (711-065-152) obtained from
Jackson ImmunoResearch Laboratories, followed by PE-conju-
gated streptavidin (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20032177/DC1). The clones in Table S1 were
generated from skin biopsies of patients with pustular psoriasis
and Behcet’s disease. Acute generalized exanthematous pustulosis
(AGEP) clones were derived from positive epicutaneous test reac-
tions. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20032177/DC1. 
Results
CCR8  T Cells Predominate in Normal Human Skin. As
part of our efforts to understand the control of peripheral
Figure 1. CCR8  T cells predominate in normal human skin. Analyses
were performed with freshly isolated cells. (a) Flow cytometric detection
of CCR8 (gray histograms) and CCR9 (bold line) in T cells isolated from
human skin, lamina propria of small intestine, and peripheral blood. Peptide-
blocked control for CCR8 staining is shown as a thin line. CD4, CD8,
and CD3 denote the respective populations analyzed within the
  TCR  cell gate, and the numbers indicate percentages of CCR8- and
CCR9-positive cells, respectively. Data for skin and intestinal cells are
representative for nine and three donors, respectively. (b) Chemotactic
migration of skin T cells, gated on CD4  cells (black bars) and CD8 
(white bars), in response to chemokines as indicated. Values represent the
percentage of migrated cells as a proportion of input cells, and control denotes
the level of migration in the absence of chemokines. (c) Expression of
CLA and CD45RA on CCR8  skin T cells. Gates were set for
CD4   TCR  cells (CD4) and CD8   TCR  cells (CD8), and the
numbers refer to the percentage of cells within each quadrant. (d) Pro-
duction of various cytokines by CD4  (black bars) or CD8  (white bars)
CCR8   TCR  skin T cells. Intracellular accumulation of cytokines in
response to PMA/ionomycin was measured by flow cytometry and is ex-
pressed as percent cytokine-positive cells. Chemotaxis and cytokine pro-
duction data are representative of four independent experiments.Normal Human Skin Harbors CCR8-expressing Memory T Cells 1268
leukocyte traffic under conditions of homeostasis, T cells
were isolated from normal skin and assessed for unique pat-
terns of chemokine receptor expression. Our focus on ho-
meostatic T cell traffic required that we processed normal
healthy skin samples with the least exposure to mechanical
stress or UV light (skin specimen from abdominoplastic
surgery). Furthermore, care was taken in the choice of the
skin cell isolation procedure to prevent changes in cell mi-
gration properties and surface marker expression (i.e., skin
tissue was processed without delay and recovered leuko-
cytes were examined 2–4 h after isolation).
The majority of freshly isolated skin T cells expressed
CCR8, whereas other skin-derived leukocytes, including
monocytes/macrophages (CD1c /CD14 ), DCs (CD1c ),
or B cells (CD19 ), were negative for this chemokine
receptor (Fig. 1 a and not depicted). In clear contrast with
skin, CCR8  T cells were rare in peripheral blood (see
next paragraph), whereas gastrointestinal T cells completely
lacked CCR8 expression (Fig. 1 a). Specifically, CCR8 ex-
pression was undetectable on intraepithelial and lamina
propria CD4  and CD8  T cells from normal small intes-
tine and colon, whereas the small intestinal homing recep-
tor CCR9 was readily detected (Fig. 1 a and not depicted).
Amongst skin T cells, CCR8 was present on 55   19% SD
of CD4  cells and 77   18% SD of CD8  cells (n   9).
Skin CCR8  T cells did not express CCR4, a chemokine
receptor that is commonly observed on effector T cells
present at inflammatory skin lesions (Table I and references
29–32). These cells also lacked expression of CCR7,
thereby highlighting the peripheral, rather than lymphoid
homing propensity of these cells (2, 4). In contrast, numer-
ous cells expressed CXCR3, a chemokine receptor broadly
associated with activated T cells (2, 4). CCR5 and CCR6
positivity was  20%. In vitro chemotaxis responses to
CCL1 and I-TAC/CXCL11, but not TARC/CCL17,
LARC/CCL20, and ELC/CCL19, confirmed functional
expression (CCR8 and CXCR3) or absence (CCR4,
CCR6, and CCR7) of the corresponding receptors (Fig.
1 b).
Phenotypic and Functional Heterogeneity of Skin CCR8  T
Cells. The majority of CCR8  T cells from normal skin
carried the skin homing ligand CLA and showed clear signs
of preactivation, including high levels of CD69, low but
uniform levels of CD25, and reduced levels of   TCRs
(Fig. 1 c, Table I, and not depicted). All skin CCR8  T
cells were antigen experienced (CD45RO ), but, interest-
ingly, substantial numbers of CD4  cells and even more
CD8  cells coexpressed CD45RA, a marker typically asso-
ciated with naive or cytolytic effector T cells (Fig. 1 c and
Table I; references 5, 33). Strikingly, and in clear contrast
with peripheral blood CD8  T cells, CCR8-expressing T
cells in the skin lacked markers that are typical for cytolytic
T cells (perforin and CD57; references 5, 33 and not de-
picted). Instead, the majority of skin CD4  and CD8  T
cells produced IFN-  and TNF-  (Fig. 1 d), indicating
that antigen contact in the skin initiates preferentially type
1 T helper cell responses. Still, minor populations express-
ing the type 2 cytokines IL-4 and IL-13 or the antiinflam-
matory cytokine IL-10 were clearly distinguishable, dem-
onstrating limited functional diversity.
Preferential production of type 1 cytokines was also ob-
served in 32 T cell clones derived from single cell–sorted
CCR8  T cells isolated from normal skin (n   3). To pre-
serve functional and phenotypic characteristics, skin T cells
were expanded under nonpolarizing conditions (28). In
agreement with the results for intracellular cytokine produc-
tion by freshly isolated skin CCR8  T cells, only a few
clones secreted substantial amounts of either IL-4 or IL-10,
whereas most clones secreted large amounts of TNF-  and
IFN-  (Fig. 2 a). All clones tested produced IL-2, but not a
single one secreted detectable levels ( 50 pg/ml) of TGF- 
(unpublished data), suggesting an absence of Treg cells.
With the exception of two clones showing low-level stain-
ing, the T cell clones were predominantly negative for in-
tracellular perforin (unpublished data), which fully matches
our findings with freshly isolated skin CCR8  T cells. Of
interest, the vast majority of CCR8  T cell clones secreted
large amounts of CCL1 (50–1000 ng/ml) after stimulation
with PMA plus ionomycin, implying a positive feedback
loop in the control of CCR8  T cell recruitment (Fig. 2 b).
Of particular note, CCR8 expression was maintained, at
varying levels of intensity, on skin T cell clones, even after
four rounds of stimulation and extensive expansion (Fig. 2,
c and d), suggesting that this chemokine receptor is a stable
feature of skin surveillance T cells. This is in striking con-
trast to our findings with 37 T cell clones derived from var-
Table I. Phenotypic Heterogeneity of Human CCR8  T Cells from Skin and Blood
T cells Subset CLA CD25 CD69 CD27 CD45RO CD45RA CCR4 CCR7 CXCR3
Skin CD4  65   13a 37   7 83   9 59   9 93   8 37   10 0b 08     2
CD8  90   1.5 63   5 100 39   14 100 65   4 0 0 39   4
Blood CD25  100 100 0 100 100 0 100 40 0
CD25  11   4 0 0 100 45   5 87   3 0 64   40
Freshly isolated CCR8  T cells from skin and blood were analyzed for coexpression of various markers by flow cytometry.
aMean   SEM of three to nine independent experiments.
b0 and 100 indicate  5 and  95% positive cells, respectively.Schaerli et al. 1269
ious skin lesions (pustular psoriasis, AGEP, and Behcet’s
disease) that showed scarce CCR8 expression (4/37 posi-
tive) but elevated frequencies in CCR4 (13/37 positive)
and most notably CCR6 expression (35/37 positive; Ta-
ble S1, available at http://www.jem.org/cgi/content/full/
jem.20032177/DC1). CCR8  cells are similarly underrep-
resented in T cell clones from atopic dermatitis (34). Of
note, the distinct levels of CCR8 expression correlated
well with the degree of responsiveness of these clones to
CCL1 (Fig. 2 d). Interestingly, the expression of CLA and
CD45RA was maintained by both CD4  and CD8 
clones derived from CCR8  skin T cells (Fig. 2 d), sup-
porting our observations in fresh skin T cells and setting
these clones apart from those derived from either periph-
eral blood or sites of skin inflammation (35).
Collectively, the majority of both CD4  and CD8  T
cells in normal skin are positive for CCR8, which is in
clear contrast to the situation in peripheral blood (see next
paragraph), intestine, or inflamed skin, and our analysis re-
vealed a mixed cytokine production profile with a clear
preference for proinflammatory cytokines. Lack of cytolytic
capabilities suggests that CCR8  T cells may be more im-
portant in initiating recall responses via cytokine secretion
as opposed to elimination of target cells. Of note, our find-
ings with cutaneous CCR8  T cells do not support a close
correlation between CCR8 expression and either Treg or
Th2 cells (20, 22–27).
Distinct Populations of CCR8  T Cells in Peripheral
Blood. In clear contrast with skin, CCR8  T cells in pe-
ripheral blood were extremely infrequent ( 2% of CD4 
or CD8  cells). These rare CCR8  T cells were contained
within two distinct subpopulations that could be discrimi-
nated on the basis of CD25 expression. First, within the
CD25-negative fraction, the CCR8  cells largely coex-
Figure 2. Analysis of T cell
clones derived from skin
CCR8  T cells. Sorted CCR8 
T cells isolated from normal skin
were cloned under nonpolarizing
conditions. (a) For cytokine and
(b) CCL1 secretion analysis, 6
CD4  and 26 CD8  T cell
clones were stimulated with
PMA/ionomycin for 24 h, and
cell-free supernatants were tested
in ELISA. (c) Expression of
CCR8 by T cell clones, as deter-
mined by flow cytometry. Per-
cent (%) CCR8  refers to the
fraction of CCR8-positive cells
present within individual clones.
(d) Detailed analysis of three
clones representing high, inter-
mediate, and low level expression
of CCR8. Cells stained with
anti-CCR8 antibodies (left,
shaded  histogram) or peptide-
blocked anti-CCR8 (unshaded
histogram). Numbers in paren-
theses indicate the clone number,
whereas numbers above the gate
lines refer to the percentage of
cells positive for CCR8. The
corresponding center panels show
chemotactic responses of the
same clones toward CCL1, ex-
pressed as the number of migrated
cells counted (mean of triplicate
wells    SEM) in five high-
power fields. Background migra-
tion in the absence of chemokine
is indicated by open circles.
The  expression of CLA versus
CD45RA, with the percentage
of cells positive within each
quadrant indicated (right).Normal Human Skin Harbors CCR8-expressing Memory T Cells 1270
pressed CD45RA and CD45RO, whereas CD45RO sin-
gle-positive memory cells were less frequent (Fig. 3 a and
Table I). These CCR8  T cells lacked expression of
CCR4 and did not bear markers of activation (CD69,
HLA-DR, and CXCR3), but 10–20% were positive for
CLA. They were too infrequent in peripheral blood for de-
tailed analysis and, therefore, primary lines were generated
by in vitro culture of freshly sorted CCR8 CD4  or
CCR8 CD8  T cells. Virtually all cultured T cells coex-
pressed CD45RA and CD45RO, and numerous cells
maintained CCR8 expression and expressed CLA (Fig. 3
b), thereby closely resembling T cells from normal skin.
Culturing under nonpolarizing conditions did not affect
their phenotype (unpublished data). Of interest, these cells
responded well in a chemotaxis assay to CCL1, but failed
to migrate to CCL19 and CCL25, which reflects the ab-
sence of CCR7 and CCR9, respectively, and their exclu-
sion from LNs and intestinal tissue (Fig. 3 c). Most ( 95%)
cultured T cells produced TNF- , 30–40% produced IFN- ,
and 10% were IL-4  (IL-5  and IL-10  cells were  5%;
unpublished data). In control lines derived from sorted
CCR8-negative blood T cells, CD45RO single-positive,
CLA-negative cells predominated (unpublished data). Ap-
parently, within the CD25-negative fraction of peripheral
blood, CCR8 expression is associated with CD45RA 
cells that secrete proinflammatory cytokines and up-regu-
late CLA during culture. These findings compare favorably
with those obtained for skin CCR8  T cells (Table I).
Recently, a subset of CD4 CD25  Treg cells in periph-
eral blood was shown to express CCR8 mRNA and to re-
spond to CCL1 (20, 26). These CCR8  cells could repre-
sent “natural” Treg cells derived from CCR8 CD25 
thymocytes (20, 21). Coexpression of CLA and CCR4
suggests that circulating CCL1-responsive Treg cells prefer-
entially home to inflamed skin tissue (20, 36). Using our
anti-CCR8 antibody reagent, we confirm the presence
of low level CCR8  T cells among CD4 CD25  and
CD8 CD25  T cells (not depicted), which also coex-
pressed CLA, CCR4, and CD45RO, but not CD45RA
(Fig. 4 a and not depicted). Of note, the CCR8  fraction of
CD4 CD25  Treg cells was able to suppress T cell prolifer-
ation during in vitro coculture, and was equally potent as
the two CCR8-negative subsets distinguished by presence
or absence of CLA expression (Fig. 4 b and reference 37).
Finally, CD4 CD25  T cells, and in particular those coex-
pressing CLA, strongly migrated in response to CCL17 and
less so to CTACK/CCL27 and CCL1, in agreement with
the distribution of the corresponding chemokine receptors
(CCR4, CCR10, and CCR8) in these cells (Fig. 4 c
and 29–32, 38, 39). Presently, it is unclear whether these
CCR8  Treg cells can home to the skin, although the pre-
dominant phenotype of skin CCR8  T cells (production of
TNF- , IFN- , and IL-2, but not TGF- , as well as lack of
CCR4, but presence of CD45RA) implies that CCR8 
Treg cells are not a major component at this site.
Localization of CCL1 in Normal Human Skin. Scattered
cells in the superficial plexus and epidermis of normal
healthy skin stained positive for CCL1 protein, as deter-
mined by immunohistochemistry (Fig. 5). Colocalization of
CCL1 with CD31  endothelial cells was frequently ob-
served in sequential skin sections (Fig. 5, a and b) and was
confirmed in double immunofluorescence analysis (Fig. 5, f
Figure 3. Expression of CCR8 on a minor subset of CD25  peripheral
blood T cells. (a) Characterization of CCR8 expression on freshly isolated,
CD25-depleted CD4  (top) or CD8  (bottom) T cells. (left) Some dot
plots demonstrate staining for CCR8 versus side scatter, whereas (right)
others demonstrate expression of CD45RO and CD45RA on cells gated
for absence (R1) or presence (R2) of CCR8 expression. (b) Characterization
of CCR8, CLA, CD45RA, and CD45RO expression on T cell lines derived
from sorted CCR8  cells corresponding to gates R2 in a. Numbers in a
and b represent the percentage of cells within each quadrant. (c) Chemo-
tactic migration of cultured CD4  T cells as shown in b in response to
chemokines as indicated. Migration is expressed as chemotactic index,
which is the ratio of cells migrated in response to chemokines versus medium
(no chemokine). CD8  T cell lines gave similar results (not depicted).
Data are representative of three independent experiments.Schaerli et al. 1271
and g). Antibodies to CD31 stain blood endothelia more
brightly than lymphatic endothelia, suggesting an involve-
ment of CCL1 in the recruitment of blood CCR8  cells. In
contrast, this chemokine probably does not play a role in
the exit of tissue-resident CCR8  cells because lymphatic
vessels, identified by podoplanin staining (40, 41), were
negative for CCL1 (Fig. 5 b). 57% of CD31  vessels (717/
1,258 positive; n   3) stained positive for CCL1, although
the actual degree of CCL1 positivity might be even higher
due to a patchy expression profile of this chemokine (Fig.
S2, available at http://www.jem.org/cgi/content/full/jem.
20032177/DC1). CCL1 and CD31 also differed in their
subcellular localization, with staining for CCL1 being more
diffuse, whereas CD31 staining was highest at endothelial
cell junctions (Fig. 5 g). Mononuclear cells positive for
CCL1 were also occasionally detected within the perivascu-
lar infiltrates; however, CCL1 expression by T cells at this
location was extremely rare (Fig. 5, c and g). In the epider-
mis of normal healthy skin, melanocytes and LCs, but not
keratinocytes, produced CCL1, characterizing an expression
profile not previously seen with chemokines. In sequential
sections, CCL1 immunostaining overlapped with loosely
scattered melanocytes interspersed in the basal layer of kera-
tinocytes that stained positive for melan-A and LCs in the
basal and suprabasal layers of the epidermis showing strong
staining for S-100 and CD1a (Fig. 5, d and e). In confirma-
tion, colocalization of CCL1 with LCs and melanocytes
were readily observed by double immunofluorescence anal-
ysis (Fig. 5, h and i). Numerous LCs, identified by staining
for either S-100 or vimentin (42), were found to express
CCL1. Melanocytes in the basal layer of keratinocytes,
identified by differential staining for S-100 (dim) and vi-
mentin (bright), also appeared to secrete this chemokine.
Staining for CCL1 was more intense in dendritic processes
as opposed to the central body of LCs and melanocytes (Fig.
5, h and i, and Fig. S2). Of note, no CCL1 staining was
observed in epidermal keratinocytes or dermal fibroblasts,
macrophages or B cells. In agreement with the scattered dis-
tribution of CCL1-producing cells, CCL1 mRNA was de-
tected in unfractionated skin tissue by RT-PCR but not by
Northern blot analysis (unpublished data).
Discussion
The constitutive recruitment of immune surveillance T
cells critically depends on chemokines that are expressed at
strategic locations in healthy peripheral tissue. In addition,
immune surveillance T cells need to express inflammation-
independent address cues, including adhesion molecules
and receptors for corresponding tissue-selective chemo-
kines. Those cues, which determine inflammatory- or LN-
homing in T cells, are obsolete. Here, we provide evidence
that CCL1 and its only receptor CCR8 meet both require-
ments that are essential for controlling cutaneous homeo-
static T cell traffic: selective expression of CCR8 by skin-
homing memory T cells and constitutive production of
CCL1 in healthy (noninflamed) skin. Possibly, CCL1 may
also contribute to the survival of local (CCR8 ) immune
surveillance T cells. This notion is supported by previous
studies demonstrating an antiapoptotic effect of CCL1 on
cells in vitro (43–46).
CCR8 is present on the majority of T cells isolated from
normal human skin, but is absent on T cells from small in-
testine, which are characterized by CCR9 expression and
colon. In agreement with previous studies (14–17, 26),
CCR8  T cells are scarce in peripheral blood, indicating
that healthy skin is their primary site of residence. Of note,
CCR8 expression is not induced on unfractionated pe-
ripheral blood T cells during in vitro stimulation (PHA,
Th1/Th2-polarizing conditions, and superantigen-present-
Figure 4. A small subset of peripheral blood CD4 CD25 
regulatory T cells expresses CCR8. (a) CCR8 expression
(shaded histograms) was analyzed on positively selected
CD4 CD25  peripheral blood T cells after gating for CLA 
(R1) and CLA  (R2) cells. Expression of CCR4 is shown
in bold lines, and control stainings are shown in thin lines.
(b) CCR8-expressing CD4 CD25  T cells suppress proliferation
of autologous CD4  memory T cells as measured by [3H]thymi-
dine incorporation after 5 d coculture in the presence of irradiated
heterologous PBMCs. Suppressive activity of sorted CCR8 
Treg cells was compared with the two major subsets of
CCR8-negative Treg cells distinguished by the presence
(CLA CCR8 CD25 ) or absence (CLA CCR8 CD25 ) of
CLA. Control denotes T cell proliferation in the absence of
autologous Treg cells. (c) CLA  Treg cells show reduced migra-
tion responses to CCL1. Migration of CLA  (black bars) and
CLA  (white bars) Treg cells in response to indicated chemo-
kines is expressed as migrated cells in percentage of input cells.
CCR8 expression and function data are representative of three
to seven independent experiments.Normal Human Skin Harbors CCR8-expressing Memory T Cells 1272
ing DCs), supporting the notion that induction of cell sur-
face CCR8 expression requires “skin-specific” costimulation
(47–49). However, this chemokine receptor is not induced
under in vitro conditions favoring CLA expression (refer-
ence 50 and unpublished data). Of note, sorted CCR8 
skin T cells maintained their characteristic level of CCR8
during repeated rounds of in vitro expansion. The identifi-
cation of CCR8 as a stable marker for skin immune sur-
veillance T cells will enable us to examine the formation of
such cells during an immune response and, eventually, clar-
ify their relationship to the fraction of CCR8-negative T
cells present in healthy skin. Lack of cytolytic function in
CD8  T cells suggests that the process of in vivo CCR8
induction occurs separately from effector cell generation.
CCL1, the selective and only ligand for CCR8, is
present at critical sites for recruitment and tissue localiza-
tion of blood CCR8  cells, including blood portals (vascu-
lature in the superficial dermal plexus) and epidermis (me-
lanocytes and LCs). CCL1 production by LCs and
melanocytes suggests that this chemokine controls the
colocalization of memory T cells with epidermal sentinel
cells for steady-state surveillance and optimal response to
local infection and tissue damage. Preliminary data indicate
that the vascular and epidermal expression of CCL1 is not
greatly enhanced during skin inflammation (psoriasis and
atopic dermatitis; unpublished data), further arguing for a
principal role of this chemokine system in the control of
homeostatic as opposed to inflammatory T cell traffic. This
fully agrees with the general absence of CCR8 expression
in cultured T cells derived from various inflammatory skin
lesions. In addition, RNA dot-blot and Northern blot hy-
bridization analysis excludes alternative tissues with promi-
nent CCL1 expression (unpublished data), supporting our
view that this chemokine is selective for skin-homing T
cells. As an exception, CCL1 is expressed in the thymus
and, thus, may contribute to thymocyte development and/
or Treg cell generation (20). We did not detect CCL1 se-
cretion in primary cultures of human keratinocytes and
dermal fibroblasts, irrespective of the culture conditions
(treatment with IL-1, TNF- , IFN- , LPS, etc.), putting
it apart from most other chemokines (reference 4 and un-
published data). However, in vitro–stimulated CCR8 
skin T cells produced substantial amounts of this chemo-
kine, suggesting a positive feedback mechanism in the re-
cruitment of immune surveillance T cells to the site of ini-
tial pathogen exposure.
Figure 5. Localization of CCL1
in normal human skin. Immuno-
histochemistry was performed on
paraffin-embedded sections from
healthy abdominal skin tissue.
(a) CCL1 (red staining) is shown
in scattered cells throughout the
superficial dermal plexus and epi-
dermis; inset depicts isotype con-
trol antibody staining. (b) Staining
of serial skin sections demon-
strates overlapping expression of
CCL1 and CD31 (blood vessels),
but not podoplanin (lymphatic
vessels) within the superficial
dermal plexus. (c) Sequential for
CCL1 and CD3 excludes T cells
as major CCL1 producers. (d)
Serial section analysis of healthy
epidermis indicates CCL1 ex-
pression in melan-A–positive
melanocytes in the basal layer of
keratinocytes and S-100–positive
LCs in the upper epidermis. (e)
Serial staining for CCL1 and
CD1a in normal epidermis. (f and
g) Double immunofluorescence
analysis demonstrates the presence
of CCL1 (red) in CD31-positive
dermal microvessels (green). (h
and i) In agreement with serial
section analysis, LCs (S-100bright,
vimentinbright, in green) in the
upper epidermis and melanocytes
(S-100dim, vimentinbright, in green)
in the basal keratinocyte layer co-
express CCL1 (red). Asterisks
mark nonspecific staining of stra-
tum corneum.Schaerli et al. 1273
Other chemokines with known expression in normal
skin include SDF-1/CXCL12 (51), BRAK/CXCL14 (52,
53), CCL27 (38, 54), and CCL20 (55). However, these
chemokines are also found in other epithelial tissues and
neither shows selectivity for cutaneous memory T cells.
CCL27, the ligand for CCR10, is highly up-regulated in
inflamed skin and is known to orchestrate, together with
the CCR4 ligands CCL17 and MDC/CCL22, the compo-
sition of effector T cells at murine skin lesions (38, 54, 56).
CCR10 is enriched among CLA CD4  effector T cells as
well as gut-homing plasma B cells (32, 38, 39, 57–59),
whereas CCR4 shows preference for effector CD4  T cells
with (CLA ) and without (CLA ) skin-homing phenotype
(29–32, 60). Both receptors are less frequent on CD8  as
opposed to CD4  blood T cells. In summary, these che-
mokines and their receptors represent unlikely candidates
for controlling memory T cell localization within healthy
human skin.
Skin CCR8  T cells secrete cytokines that may be in-
volved in the initiation of type 1 recall responses (TNF- 
and IFN- ), whereas cytokines typical of Th2 cells (IL-4
and IL-13) or Treg cells (IL-10 and TGF- ) were low to
undetectable. Therefore, our results support the view that,
at least in normal skin, CCR8 expression is not confined to
Th2 and/or Treg cells (20, 22–27). We could confirm the
expression of low levels of CCR8 by peripheral blood
CD25  Treg cells, suggesting that some cutaneous CCR8 
T cells may have Treg function. However, several features
in cutaneous CCR8  T cells, including cytokine secretion,
chemokine receptor, and CD45RA expression profiles as
well as unproblematic in vitro culture, argue against a prev-
alence of Treg cells in normal skin. We will examine the
distribution of the Treg cell marker FoxP3 among skin T
cells as soon as reagents for immunohistochemistry are avail-
able (61). The alternative and equally minor subset of
CCR8  T cells in peripheral blood, characterized by lack of
CD25 but presence of CD45RA and CLA, resembles better
CCR8  immune surveillance T cells within skin and, thus,
may represent their circulating precursors. Importantly, our
studies demonstrate that normal healthy skin but not pe-
ripheral blood is the major reservoir of CCR8  T cells.
We propose that CCL1 and CCR8 contribute in multi-
ple ways to immune protection of the skin (11–13). First,
the constitutive production of CCL1 by noninflamed skin
endothelium is likely to mediate the steady-state extravasa-
tion of CCR8  blood precursors of skin-tropic immune
surveillance T cells. Second, CCL1 produced by LCs and
melanocytes may allow colocalization of the recruited T
cells with epidermal APCs, allowing the detection of
MHC–peptide complexes. Successful TCR engagement
together with appropriate costimulation will trigger an im-
mune defense program that may involve monocytes, gran-
ulocytes, inflammatory T cells, and antibodies. In this
scheme, activated immune surveillance T cells are proposed
to play a dual role. Secretion of TNF-  and IFN-  initiates
inflammatory sequelae in local sentinel and tissue cells,
leading to acute phase responses via induction of inflamma-
tory chemokines, up-regulation of vascular adhesion recep-
tors, and consequent recruitment of leukocytes of the in-
nate immune system. Antigen specificity in memory T cells
provides enhanced tissue protection while allowing the in-
duction of selective proinflammatory responses in case of
local antigenic contact. In addition, immune surveillance T
cells may function as ambassadors of cutaneous LNs, and
their relocation to draining LNs may accelerate appropriate
T and B cell responses. Understanding the mechanisms by
which immune surveillance T cells are recruited and posi-
tioned within the skin provides an important insight into
the biology of these cells, and potentially a means by which
to manipulate the cutaneous immune system for vaccina-
tion purposes. Here, we provide evidence that CCR8 ,
together with its single ligand CCL1, represent the first
chemokine system that meets the requirements for con-
trolling T cell–mediated immune protection in normal,
healthy skin.
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